Variants of uncertain significance in the era of high-throughput genome sequencing: a lesson from breast and ovary cancers
- PMID: 32127026
- PMCID: PMC7055088
- DOI: 10.1186/s13046-020-01554-6
Variants of uncertain significance in the era of high-throughput genome sequencing: a lesson from breast and ovary cancers
Abstract
The promising expectations about personalized medicine have opened the path to routine large-scale sequencing and increased the importance of genetic counseling for hereditary cancers, among which hereditary breast and ovary cancers (HBOC) have a major impact. High-throughput sequencing, or Next-Generation Sequencing (NGS), has improved cancer patient management, ameliorating diagnosis and treatment decisions. In addition to its undeniable clinical utility, NGS is also unveiling a large number of variants that we are still not able to clearly define and classify, the variants of uncertain significance (VUS), which account for about 40% of total variants. At present, VUS use in the clinical context is challenging. Medical reports may omit this kind of data and, even when included, they limit the clinical utility of genetic information. This has prompted the scientific community to seek easily applicable tests to accurately classify VUS and increase the amount of usable information from NGS data. In this review, we will focus on NGS and classification systems for VUS investigation, with particular attention on HBOC-related genes and in vitro functional tests developed for ameliorating and accelerating variant classification in cancer.
Keywords: ATM gene; Functional tests; Germline and somatic mutations; Next-generation sequencing; Variant classification; Variants of uncertain significance.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.Clin Biochem. 2020 Feb;76:17-23. doi: 10.1016/j.clinbiochem.2019.11.014. Epub 2019 Nov 28. Clin Biochem. 2020. PMID: 31786208
-
BRCA1 and BRCA2 Testing through Next Generation Sequencing in a Small Cohort of Italian Breast/Ovarian Cancer Patients: Novel Pathogenic and Unknown Clinical Significance Variants.Int J Mol Sci. 2019 Jul 12;20(14):3442. doi: 10.3390/ijms20143442. Int J Mol Sci. 2019. PMID: 31336956 Free PMC article.
-
Power of pedigree likelihood analysis in extended pedigrees to classify rare variants of uncertain significance in cancer risk genes.Fam Cancer. 2017 Oct;16(4):611-620. doi: 10.1007/s10689-017-9989-6. Fam Cancer. 2017. PMID: 28534081 Free PMC article.
-
[Detecting Large Germline Rearrangements of BRCA1 by Next Generation Tumor Sequencing].Mol Biol (Mosk). 2020 May-Jun;54(4):688-698. doi: 10.31857/S0026898420040114. Mol Biol (Mosk). 2020. PMID: 32840490 Review. Russian.
-
DNA repair-related functional assays for the classification of BRCA1 and BRCA2 variants: a critical review and needs assessment.J Med Genet. 2017 Nov;54(11):721-731. doi: 10.1136/jmedgenet-2017-104707. Epub 2017 Sep 2. J Med Genet. 2017. PMID: 28866612 Review.
Cited by
-
Prevalence of Variants of Uncertain Significance in Patients Undergoing Genetic Testing for Hereditary Breast and Ovarian Cancer and Lynch Syndrome.Cancers (Basel). 2023 Dec 8;15(24):5762. doi: 10.3390/cancers15245762. Cancers (Basel). 2023. PMID: 38136308 Free PMC article.
-
Clinical genetics evaluation and testing of connective tissue disorders: a cross-sectional study.BMC Med Genomics. 2022 Aug 2;15(1):169. doi: 10.1186/s12920-022-01321-w. BMC Med Genomics. 2022. PMID: 35918752 Free PMC article.
-
Experiences of individuals with a variant of uncertain significance on genetic testing for hereditary cancer risks: a mixed method systematic review.J Community Genet. 2022 Aug;13(4):371-379. doi: 10.1007/s12687-022-00600-4. Epub 2022 Jul 12. J Community Genet. 2022. PMID: 35819584 Free PMC article. Review.
-
Real-World Efficacy and Safety of PARP Inhibitors in Recurrent Ovarian Cancer Patients With Somatic BRCA and Other Homologous Recombination Gene Mutations.Ann Pharmacother. 2023 Oct;57(10):1162-1171. doi: 10.1177/10600280221149136. Epub 2023 Jan 18. Ann Pharmacother. 2023. PMID: 36651235 Free PMC article.
-
Multi-gene panel testing and association analysis in Cypriot breast cancer cases and controls.Front Genet. 2023 Sep 18;14:1248492. doi: 10.3389/fgene.2023.1248492. eCollection 2023. Front Genet. 2023. PMID: 37790698 Free PMC article.
References
Publication types
MeSH terms
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous